Moreover, the humanised anti-NKG2A mAb, monalizumab, unleashed the activity of both CD8+ T and NK cells in two murine lymphoma tumour models (A20 B cell lymphoma and RMA-Rae1β) in combination with anti-PD-1/PD-L1 Ab blockade [68]. The gene discussed is KLRC1; the disease is neoplasm.